As of May 16, 2025, Protagenic Therapeutics, Inc. was acquired by Phytanix Bio, Inc., in a reverse merger transaction. Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. Show more

Location: 149 Fifth Avenue, New York, NY, 10010, United States | Website: https://www.protagenic.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

3.204M

52 Wk Range

$2.35 - $15.54

Previous Close

$3.69

Open

$3.67

Volume

100,262

Day Range

$3.51 - $3.70

Enterprise Value

1.277M

Cash

873K

Avg Qtr Burn

-906.3K

Insider Ownership

11.21%

Institutional Own.

4.75%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PT00114 Details Addiction, Post-traumatic stress disorder, Treatment Resistant Depression, Social Anxiety Disorder	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.